Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Wednesday before market open. Here’s what to expect.
AbbVie beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $15.78 billion, up 9.1% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ constant currency revenue estimates but a miss of analysts’ full-year EPS guidance estimates.
Is AbbVie a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting AbbVie’s revenue to grow 7.6% year on year to $16.25 billion, improving from the 5.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.65 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AbbVie has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.3% on average.
Looking at AbbVie’s peers in the biotechnology segment, only Regeneron has reported results so far. It beat analysts’ revenue estimates by 2.7%, delivering year-on-year sales growth of 2.5%. The stock price was unchanged following the results.
Read our full analysis of Regeneron’s earnings results here.Investors in the biotechnology segment have had steady hands going into earnings, with share prices flat over the last month. AbbVie is up 2.7% during the same time and is heading into earnings with an average analyst price target of $243.35 (compared to the current share price of $225.56).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.